Foundational characteristics of cancer include proliferation, angiogenesis, migration, evasion of apoptosis, and cellular immortality. Find key markers for these cellular processes and antibodies to detect them.
The SUMOplot™ Analysis Program predicts and scores sumoylation sites in your protein. SUMOylation is a post-translational modification involved in various cellular processes, such as nuclear-cytosolic transport, transcriptional regulation, apoptosis, protein stability, response to stress, and progression through the cell cycle.
The Autophagy Receptor Motif Plotter predicts and scores autophagy receptor binding sites in your protein. Identifying proteins connected to this pathway is critical to understanding the role of autophagy in physiological as well as pathological processes such as development, differentiation, neurodegenerative diseases, stress, infection, and cancer.
TRIM34 Antibody (N-term) Blocking peptide
Synthetic peptide
- SPECIFICATION
- CITATIONS
- PROTOCOLS
- BACKGROUND
| Primary Accession | Q9BYJ4 |
|---|---|
| Clone Names | 100408320 |
| Gene ID | 53840 |
|---|---|
| Other Names | Tripartite motif-containing protein 34, Interferon-responsive finger protein 1, RING finger protein 21, TRIM34, IFP1, RNF21 |
| Target/Specificity | The synthetic peptide sequence used to generate the antibody AP13644a was selected from the N-term region of TRIM34. A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay. |
| Format | Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed. |
| Storage | Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C. |
| Precautions | This product is for research use only. Not for use in diagnostic or therapeutic procedures. |
| Name | TRIM34 |
|---|---|
| Synonyms | IFP1, RNF21 |
| Function | Functions as antiviral protein and contributes to the defense against retroviral infections (PubMed:17156811, PubMed:32282853). Acts as a capsid-specific restriction factor with the help of TRIM5 and prevents infection from non-host-adapted retroviruses (PubMed:32282853). During influenza A virus infection, promotes programmed cell death by targeting ZBP1 for 'Lys-63'-linked polyubiquitination (PubMed:35065966). In turn, promotes ZBP1 recruitment of RIPK3 to mediate virus-induced programmed necrosis (PubMed:35065966). Negatively regulates the function of mitochondria by enhancing mitochondrial depolarization leading to cytochrome c release and mitochondria-dependent apoptosis (PubMed:31956709). Promotes also the formation of multinucleated giant cells by means of cell fusion and phagocytosis in epithelial cells (PubMed:31487507). |
| Cellular Location | Cytoplasm Mitochondrion. Note=Localizes in cytoplasmic bodies together with TRIM5 and incoming HIV-1 capsids during infection. |
| Tissue Location | [Isoform 1]: Is the most abundant form. It is highly expressed in the placenta, spleen, colon and peripheral blood leukocytes. |
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abcepta to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
info@abcepta.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
Background
The protein encoded by this gene is a member of thetripartite motif (TRIM) family. The TRIM motif includes threezinc-binding domains, a RING, B-box type 1 and B-box type 2 domain,and a coiled-coil region. Expression of this gene is up-regulatedby interferon. This gene is mapped to chromosome 11p15, where itresides within a TRIM gene cluster. Alternative splicing results inmultiple transcript variants. A read-through transcript from theupstream TRIM6 gene has also been observed, which results in afusion product from these neighboring family members. [provided byRefSeq].
References
Sawyer, S.L., et al. PLoS Pathog. 3 (12), E197 (2007) :Li, X., et al. Virology 360(2):419-433(2007)Zhang, F., et al. Virology 353(2):396-409(2006)Li, X., et al. J. Virol. 80(13):6198-6206(2006)Reymond, A., et al. EMBO J. 20(9):2140-2151(2001)
If you have used an Abcepta product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at tech@abcepta.com.
Ordering Information
Other Products
Shipping Information
